econintersect .com

FREE NEWSLETTER: Econintersect sends a nightly newsletter highlighting news events of the day, and providing a summary of new articles posted on the website. Econintersect will not sell or pass your email address to others per our privacy policy. You can cancel this subscription at any time by selecting the unsubscribing link in the footer of each email.

posted on 23 July 2016

Billions Are Spent On Clinical Research That Gets Ignored - Here's The Answer

from The Conversation

-- this post authored by Aileen Grant, and Mary Wells, University of Stirling; and Shaun Treweek, University of Aberdeen

Heart failure is a major killer, affecting well over a million people in the UK alone. We now have over 20 years' worth of evidence from clinical trials that show strong benefits for a package of treatment involving not only drugs and devices but also where patients stay, how they are cared for and how the different healthcare professionals work with one another. Yet in many cases, doctors are not acting on the findings.

This is just one example of a major problem in healthcare across the world. Billions of pounds are spent each year researching clinical treatments, but a staggering 85% of all research ends up not being put into practice - much of it passed over for reasons that could be avoided. Even when research findings are taken up by clinicians and those in charge of health policy, the average delay between publication and practice is 17 years.

The more medical conditions you consider, the more examples crop up. Research into a new care package for chronic kidney disease was shown to be effective, for example, but it is not implemented by GPs because they are struggling to prioritise it over other conditions and competing demands.

Or take Bell's palsy, a condition where muscle weaknesses cause a sufferer's facial features to droop on one side. Many patients are not being given the treatment shown in trials to be the most effective. In lung cancer of the non-small cells, meanwhile, a new radiotherapy treatment has been proven to be a better cure than conventional radiotherapy. Yet it is not widely given because of doctors' preferences and the practicalities of providing it in hospitals.

Trials and context

So what's the problem? This gap between evidence and practice has produced a whole field of research in its own right called implementation science or knowledge transfer, which has identified various issues. Some trials are not of high enough quality. This can be for any number of reasons including problems with the way participants are selected, conducting the wrong trials or conducting the right trials the wrong way.

Other trials are not published because they did not produce a result in favour of the new treatment being tested. Initiatives such as the All Trials campaign aim to get all trials registered and their results published so that we can see the full picture, not a distorted one.

Yet this won't solve everything. This is because one of the biggest problems, which has perhaps not received enough attention in the past, is that research findings are frequently much less meaningful to clinicians and policymakers in the real world than they could be.

Trials don't collect sufficient information about the context in which they were conducted, or about how contextual factors affected the results. So outside the direct trial setting, the results can either be less useful or it can be hard to judge whether they will be useful or not.

Never simple. Jaroon Magnuch

Even a seemingly simple switch from one pill to another can stumble because of things like its cost and availability, patient preferences, or beliefs among staff as to the benefits of the old drug. And when it comes to complex team-delivered treatments such as surgery or rehabilitation, the scope for context to matter increases enormously.

The need to look closer

Many specialists believe the answer is to run separate studies alongside clinical trials that aim to understand their context, their processes and all the relevant variables that come into play. These are expensive, though not prohibitively so, and work is going on into how to make them cheaper. The UK Medical Research Council last year published guidance on how such studies should be conducted.

One thing lacking from this guidance, however, was much explanation of how context should be explored in these studies. This is because we've yet to fully understand the problem. An overview of 70 reviews looking at why GPs and other professionals in primary care don't put research findings into practice recently concluded that future research needs to concentrate on how and why contextual factors play a part.

GP's perspective still poorly understood. Nonwarit

There also appears to be another obstacle. There is growing pressure to prioritise funding for research that has the greatest impact on clinical care. Methodology research into the context problem doesn't have an immediate impact on clinical care, which makes it harder to attract funding. It currently attracts only a small part of the overall budget for healthcare research.

The paradox is that until we properly understand how context influences trials, their results will continue failing to achieve their potential impact on clinical care. In other words, 85% of research will continue to be wasted. When the alternative is that millions of people do not get the best treatment available, the only logical move is to make this a top priority.

The ConversationAileen Grant, Research Fellow, University of Stirling; Mary Wells, , University of Stirling, and Shaun Treweek, Professor of Health Services Research, University of Aberdeen

This article was originally published on The Conversation. Read the original article.

>>>>> Scroll down to view and make comments <<<<<<

Click here for Historical News Post Listing

Make a Comment

Econintersect wants your comments, data and opinion on the articles posted. You can also comment using Facebook directly using he comment block below.

Econintersect Contributors

Print this page or create a PDF file of this page
Print Friendly and PDF

The growing use of ad blocking software is creating a shortfall in covering our fixed expenses. Please consider a donation to Econintersect to allow continuing output of quality and balanced financial and economic news and analysis.

Keep up with economic news using our dynamic economic newspapers with the largest international coverage on the internet
Asia / Pacific
Middle East / Africa
USA Government

 navigate econintersect .com


Analysis Blog
News Blog
Investing Blog
Opinion Blog
Precious Metals Blog
Markets Blog
Video of the Day


Asia / Pacific
Middle East / Africa
USA Government

RSS Feeds / Social Media

Combined Econintersect Feed

Free Newsletter

Marketplace - Books & More

Economic Forecast

Content Contribution



  Top Economics Site Contributor TalkMarkets Contributor Finance Blogs Free PageRank Checker Active Search Results Google+

This Web Page by Steven Hansen ---- Copyright 2010 - 2018 Econintersect LLC - all rights reserved